argyrotsipi/train-dataset huggingface dataset:
Delivery of Public Services — House of Commons, 2022-06-28
Topic: Health
Margaret Greenwood (Labour, Centre-left): The hon. Lady is talking about the discharge from hospital process that was brought into law through the Health and Care Act 2022. Is she aware that the Government do not even know the clinical outcomes of these people? I have submitted written questions on a number of occasions to ask how many patients who were discharged under the discharge to assess process were readmitted to hospital within 30 days, but the Government do not know. Does she agree that the Government should really have done the work and found that out before going ahead with a process that puts very vulnerable patients at risk?
Life Sciences — House of Commons, 2017-01-31
Topic: Health
Jo Johnson (Conservative, Centre-right): We invest £2 billion a year in health life sciences research through our research councils and the National Institute for Health Research. Through funding for the biomedical catalyst, we are helping businesses to bring that research to market. We announced in the new industrial strategy that Sir John Bell will be leading work on a strategy to make the UK the best place in the world to invest in life sciences.
Neonatal Care (Leave and Pay) Bill — House of Commons, 2022-07-15
Topic: Health
Ruth Lorraine Jones (Labour, Centre-left): Thank you for calling me and for indulging me this morning, Madam Deputy Speaker. I was not going to speak in this debate but I have been so inspired by hearing everybody else that I feel that I must add my personal support, and that of my party, to the Bill. I thank the hon. Member for Cumbernauld, Kilsyth and Kirkintilloch East (Stuart C. McDonald) for bringing it forward, as it is so important. I also thank you, Madam Deputy Speaker, for your eloquent words highlighting exactly why we are doing this As a former physiotherapist—I worked as a paediatric physio for many years—I am proud to say that I set up the physio service at what was the special care baby unit at the Royal Gwent Hospital in my constituency; obviously, it is now known as the neonatal intensive care unit. It was set up because the evidence was clear that parents need to be with their children at that stage when their babies are born. We are talking about babies born as young as 24 weeks, which gives them 16 weeks to get to the normal gestational age, so it is really important that parents are there from the very beginning. The scientific research, which I am proud to say I was partly involved with, shows just how important bonding with parents is at that age. We have heard eloquent speeches from others about the importance of breastfeeding, the weight gain and the calming ability of what physios would call "handling", what we here would call "cuddles" and, obviously, what we in Wales we would call "cwtshys". It is very important that these cwtshys are there, from mums and dads—we must not forget dads, as it is so important that they are able to be included We also need to remember what happens during the transition home. After perhaps 10 weeks having been spent in a very scientific and clinical area, taking that little precious baby home is very scary for parents. It is so important that dad is there with mum to support with that transition back. I endorse all the points made by other eloquent speakers in this debate, but I urge the Minister to do all she can to make sure that the Bill progresses, despite any turbulence we might be having because of leadership elections. It is really important that we get this Bill on the statute book to benefit parents and babies across the UK.
Medical Research — House of Commons, 2017-01-31
Topic: Health
Jo Johnson (Conservative, Centre-right): Between 2010-11 and 2014-15, the MRC spent £13.3 million on autism research, and it always welcomes high-quality applications for support on any aspect of human health. Such applications are subject to peer review and are judged in open competition. The Department of Health, through the National Institute for Health Research, also funds research in this area, and the MRC’s centre for neurodevelopmental disorders at King’s College London opened recently, in November.
European Union (Notification of Withdrawal) Bill — House of Commons, 2017-01-31
Topic: Health
Anna Mary Soubry (Conservative, Centre-right): Will my right hon. Friend please assure us that he will be true to his claim, as a leader of the leave campaign, that £350 million a week will now be going into our NHS? Or does he agree with others who say that that figure was always false and that that was a lie?
Drug Addiction — House of Commons, 2017-01-24
Topic: Health
Questions: What steps the Government are taking to (a) treat drug addiction in prison and (b) provide education and skills training to prisoners formerly addicted to drugs to help them to find work on release.; What steps the Government are taking to (a) treat drug addiction in prison and (b) provide education and skills training to prisoners formerly addicted to drugs to help them to find work on release.; What steps the Government are taking to (a) treat drug addiction in prison and (b) provide education and skills training to prisoners formerly addicted to drugs to help them to find work on release.
Amanda Jane Solloway (Conservative, Centre-right): I have visited many prisons in my role as rapporteur on mental health for the Joint Committee on Human Rights, and one of the most consistent and challenging problems is not only treating drug addiction but preventing new psychoactive substances from entering the prison system. Will the Minister update me on the Department’s plans to prevent NPS abuse in prisons?
Drug Addiction — House of Commons, 2017-01-24
Topic: Health
Questions: What steps the Government are taking to (a) treat drug addiction in prison and (b) provide education and skills training to prisoners formerly addicted to drugs to help them to find work on release.; What steps the Government are taking to (a) treat drug addiction in prison and (b) provide education and skills training to prisoners formerly addicted to drugs to help them to find work on release.; What steps the Government are taking to (a) treat drug addiction in prison and (b) provide education and skills training to prisoners formerly addicted to drugs to help them to find work on release.; Does my hon. Friend agree that, if we are to reduce reoffending, it is vital to get prisoners off drugs and give them the skills they will need to find work in their local community on release?
Phillip James Lee (Conservative, Centre-right): My hon. Friend, who has the same profession as me, fully understands the importance of the proper treatment of substance misuse. Having successfully got off the drug, part of that is finding purpose in life, and employment is key to that.
European Union (Withdrawal) Bill — House of Lords, 2018-02-26
Topic: Health
Martin Callanan (Conservative, Centre-right): Let me first thank noble Lords very much indeed for bringing this important topic before the House today. I reassure them that the Department of Health and Social Care is actively supporting my department in its negotiations with the EU, including forming part of the negotiation team where the topic is of direct relevance to healthcare. It is also working closely with its arm’s-length bodies, the territorial offices and others across government in preparing for EU exit under all eventualities I will address this group of amendments now but I note that the noble Lord, Lord Warner, who I think is not in his place at the moment, has also tabled an amendment on health to Clause 6. This will be responded to formally when we reach that group and I note his specific interest in the subject Amendment 11, in the name of the noble Baroness, Lady Thornton, would delay the repeal of the European Communities Act 1972 until such time as the Secretary of State has set out a strategy for ensuring the mutual recognition of medicines and devices between the EU and UK. The Government have already set out a very clear offer to the EU for the UK to continue to work in partnership in the area of medicines. It is in the interests of patients and the life sciences industry for us to find a way to continue UK-EU co-operation on medical regulation, even if our precise relationship with the EU will by necessity change. Discussions are ongoing and the outcome will form part of our future relationship with the EU. We cannot and should not delay commencement of this Act until those discussions have concluded. The UK’s medicines and medical devices regulator, the MHRA, is a strong leader that will continue to ensure that medicines and medical devices are safe and effective, regardless of the outcome of negotiations and any agreement on recognition in this area. Indeed, it is currently recognised globally as an authority in its licensing and inspections In response to the questions from the noble Baroness, Lady Finlay, and the noble Lords, Lord Cormack and Lord Davies, I can be extremely clear that the UK’s preferred outcome is to find a way to continue to co-operate on medicines regulation with the EMA. We have made that extremely clear to the EU. Even though our relationship with the EMA will have to change as we leave the EU, it is in our mutual interests to continue to co-operate and share scientific expertise. We believe that desire is shared by the EU.
European Union (Withdrawal) Bill — House of Lords, 2018-02-26
Topic: Health
Martin Callanan (Conservative, Centre-right): It is obviously difficult for me to speculate on what happens if we do not achieve the outcome that we want. As I said, we strongly believe that since we contribute an awful lot of work through the MHRA—something like 40% of the EMA’s work is contributed to by UK authorities—it is in our mutual interests to continue to co-operate. If that is not possible, we will set out an alternative course of action but we believe that it is and should be.
European Union (Withdrawal) Bill — House of Lords, 2018-02-26
Topic: Health
Martin Callanan (Conservative, Centre-right): The important progress was announced in the agreement reached in December in the first phase of the negotiations. Reciprocal healthcare benefits were guaranteed for existing UK residents in the EU and for existing EU residents here. The next phase is what happens in the future.
Stem Cell Transplants — House of Commons, 2017-01-24
Topic: Health
David John Barrington Burrowes (Conservative, Centre-right): The point I am trying to make is that everyone has been on a journey of discovery and understanding in relation to the development of the life-saving potential of stem cell transplants. This is all part of a partnership involving collection, more effective transportation, research and clinical networks. We all recognise that, in this complex world, there is a risk of relapse, so the journey of treatment is a continuing one. Once someone is having treatment, they are part of that journey, and the hon. Gentleman is right to say that they should not simply be cut off and told that they have had their go. We know of many other patients with a chronic illness who go back to their doctor or to hospital because they have had a relapse. We have to recognise that that happens in this field, where we are getting better quality outcomes. There is still an issue of resistance, however, which needs extra research and clinical expertise. When a clinician says that a transplant is the only option available to that small number of patients, and when we are investing so much in ensuring that there is greater access nationally to treatments for blood disorders and blood cancers, it makes no sense to cut those people off and give them no further opportunity for treatment.
European Union (Withdrawal) Bill — House of Lords, 2018-02-26
Topic: Health
Martin Callanan (Conservative, Centre-right): I will need to write to the noble Baroness with the exact amount of billing, as I do not have those figures in front of me at the moment I turn to Amendment 353, tabled by the noble Lord, Lord Stephen. The Government already keep NHS performance and health outcomes constantly under review, including through the NHS outcomes framework, which measures a number of health indicators intended to form an overarching picture of the current state of health and care services in England. We are committed to positive and productive engagement with the devolved Administrations going forward as we seek a deal that works for the entire United Kingdom The Secretary of State for Health and Social Care also publishes an annual assessment on the performance of NHS England, including how it has met its mandate from the Government, as well as an annual report on the overall performance of the health service.
European Union (Withdrawal) Bill — House of Lords, 2018-02-26
Topic: Health
Martin Callanan (Conservative, Centre-right): I am not sure that is the case. Obviously there are people returning to the EU all the time, and different people coming to the UK to take up job offers. We can get into detailed figures, but I do not think there is any large-scale exodus of health service staff For the reasons I have set out, this amendment is both unnecessary and risks creating unwelcome new burdens at a time when that is least appropriate. I hope I have been able to provide noble Lords with sufficient reassurance.
European Union (Withdrawal) Bill — House of Lords, 2018-02-26
Topic: Health
Martin Callanan (Conservative, Centre-right): I thank my noble friend for his comments. A lot of these matters are still to be negotiated in the next phase. We made substantial progress in the first phase, and we will endeavour to ensure that we make good progress to achieve a good working relationship with the EMA and to guarantee the rights of travellers through a system similar to the European health insurance card for those travelling in future. I hope to be able to provide more information on Report.
European Union (Withdrawal) Bill — House of Lords, 2018-02-26
Topic: Health
Martin Callanan (Conservative, Centre-right): The noble Baroness has made some valuable points. On the question of data on EU staff applying to jobs in the UK, if that information is available then we will certainly share it with her. She asked what happens if there is no agreement. As I said, the MHRA already issues national licences for some 90% of medicines on the UK market. If we are no longer co-operating with the EMA on the regulation of new novel medicines, the UK will ensure that our own procedures do not lead to any delay in patient access to new medicines and are no more burdensome to industry The noble Baroness’s point about working with the devolved Administrations is a good one and we will ensure that that happens.
Stem Cell Transplants — House of Commons, 2017-01-24
Topic: Health
David John Barrington Burrowes (Conservative, Centre-right): I am the first to congratulate the Government on making that investment, and on that commitment and partnership work. Nevertheless, is there not a mismatch? The investment commitment to collections at source is no doubt meant to ensure that there are outcomes in relation to transplantation. Our issue is that it seems that, at the end of the day, when a patient gets to the second transplant, which is sadly part of the complicated life-cycle for them, we seem to be just pulling the rug from under them.
Stem Cell Transplants — House of Commons, 2017-01-24
Topic: Health
Nicola Blackwood (Conservative, Centre-right): My hon. Friend will have heard my answer on that. We are trying to address that as we go through the commissioning process by ensuring that the best possible evidence is there and that it is the most up-to-date clinical evidence, so that, through what has to be a robust prioritisation process, the second stem cell transplantation for relapse has the best possible chance. I also think that it is important that we address the other areas of stem cell transplantation to ensure that patients have the most improved outcomes at, for example, first transplant level, so that the research is available to feed through into that prioritisation process, and also so that patients have the best possible experience going through the process Finding a suitable donor is only the start of a long recovery process for patients, as Emma said very clearly to me. The report from the independent Cancer Taskforce, with which hon. Members are familiar, identified a number of ways in which people living with and beyond cancer could and should be better supported. In the case of patients receiving stem cell transplants, NHS England has set out the pathway in its service specifications. It is widely recognised that patients receiving a stem cell transplant often experience severe psychological and emotional stress. The aggressive nature of the treatment and the need for prolonged hospital stays mean that the psychological impact on patients can be particularly severe Transplant centres recognise that the long-term management of these effects is an important aspect of the transplantation process. It is important that we stay by those patients for the long term, as has been mentioned. There is also an urgent need to improve the clinical outcomes of stem cell transplants and to track those outcomes so that we have the evidence to present. The planned impact project is an important aspect in addressing the development of the best possible clinical practice. This network, supported by the charities, Anthony Nolan and Leuka, will complement the existing National Institute for Health Research clinical trials network. It aims to recruit 20% of stem transplantation patients into clinical trials. We believe that it is only through further research supported by clinical trials that the survival rates for these transplants can be improved During my recent visit to the Anthony Nolan laboratories, I was particularly impressed to see that they are involved in applying the latest genomics technology to improve the matching of donors and recipients. It is a clear example of how we are directly improving care and access through our research and through the 100,000 Genomes Project.
Stem Cell Transplants — House of Commons, 2017-01-24
Topic: Health
Nicola Blackwood (Conservative, Centre-right): The hon. Gentleman is absolutely right. It is very important that we look at the whole child as well as the psychological impacts of long-term illness—whether it is a cancer or any other kind of long-term illness. He will know that we are developing a Green Paper for children’s mental health, and I do intend, and hope, to be addressing the ways in which we can look at not only the broad spectrum of children’s mental health, but those who have particular challenges that they need to overcome. He has raised the matter with me before. I gave him a commitment that I would follow through on it, and I reassert that commitment tonight The way in which we are working on this, which is to build up the research to improve patient care and to ensure that we are allowing the NHS to deliver world-leading therapies based on genetic information, is essential to ensuring that every patient receives the appropriate treatment. That is what colleagues say they want to happen. It also highlights the importance of having the right infrastructure in place throughout the NHS, because if we do not have that, we will not be able to provide the best support That is why we announced in September an £816 million investment for biomedical research centres over the next five years. We also specifically support translational research into stem cell transplantation through the stem cell and immunotherapy research unit—one of four NIHR blood and transplant research units, each of which is a partnership between a university and NHSBT. The stem cell unit at University College London is involved in the development of new and potentially transformative forms of treatment involving immuno- therapies. Such therapies are perhaps the most exciting and promising area of cancer therapy and may eventually entirely replace the need for stem cell transplantation. I appreciate, however, that those advances cannot come soon enough for the patients mentioned tonight As ground-breaking as our research efforts undoubtedly are and as necessary as they are for the long term, we must always remember that research is not an end in itself. Ultimately, we are all working to deliver better, more targeted patient outcomes that offer hope to the thousands of people living with an incurable condition. In doing so, we must ensure that we are helping to improve the lives of those patients and their families while we work to transform NHS care for generations to come. That is what we are working to deliver. I hope that the hon. Member for Alyn and Deeside and my hon. Friend the Member for Enfield, Southgate will work with me as we try to do that Question put and agreed to.
Engagements — House of Commons, 2017-01-11
Topic: Health
Questions: Westinghouse’s Springfields site in my constituency employs more than 1,200 people in highly skilled jobs manufacturing nuclear fuel, which generates 15% of the UK’s electricity. Does my right hon. Friend agree that the nuclear industry is of crucial importance to the north-west economy? Will she continue to support the construction of a new generation of nuclear power stations to guarantee jobs in the region?
Theresa Mary May (Conservative, Centre-right): First, may I join the right hon. Gentleman in sending our condolences to the family of Lance Corporal Hetherington, who, as he said, died in a non-combat incident in Iraq? From everything I have seen and read about Lance Corporal Hetherington, he was a very fine young man. He delighted in being in the armed forces, and we are proud that such a fine young man was in our armed forces. I also join the right hon. Gentleman in expressing condolences to the family and friends of little Katie, who died so tragically The right hon. Gentleman talks about the pressures on the NHS, and we acknowledge that there are pressures on the national health service. There are always extra pressures on the NHS during the winter, but, of course, we have at the moment those added pressures of the ageing population and the growing complex needs of the population. He also refers to the British Red Cross’s term, "humanitarian crisis." I have to say to him that I think we have all seen humanitarian crises around the world, and to use that description of a national health service that last year saw 2.5 million more people treated in accident and emergency than six years ago was irresponsible and overblown.
Engagements — House of Commons, 2017-01-11
Topic: Health
Questions: Westinghouse’s Springfields site in my constituency employs more than 1,200 people in highly skilled jobs manufacturing nuclear fuel, which generates 15% of the UK’s electricity. Does my right hon. Friend agree that the nuclear industry is of crucial importance to the north-west economy? Will she continue to support the construction of a new generation of nuclear power stations to guarantee jobs in the region?
Theresa Mary May (Conservative, Centre-right): I have said to the right hon. Gentleman that I of course acknowledge that there are pressures on the national health service. The Government have put extra funding into the national health service. The fact is that we are seeing more people being treated in our NHS: 2,500 more people are treated within four hours every day in the national health service because of the Government putting in extra funding and because of the hard work of medical professionals in our national health service. It is not just a question of targets for the health service, although we continue to have a commitment to the four-hour target, as the Health Secretary has made clear. It is a question of making sure that people are provided with the appropriate care for them, and the best possible care for them in their circumstances.